Acura Pharmaceuticals, Inc. · OTC:ACUR
Acura Pharmaceuticals — Technical Presentation (April 2016)
13 slides from Acura Pharmaceuticals's technical presentation, Apr 14, 2016
Slide 1: Topline Interim Cohort 1 Results Study AP-LTX-400
CONFIDENTIAL Nasdaq: ACUR April 13, 2016 Topline Interim Cohort 1 Results Study AP - LTX - 400 (Study 400) © 2016 Acura Pharmaceuticals, Inc. All Rights Reserved
Slide 2: General Caution Regarding Forward Looking Statements
Nasdaq: ACUR General Caution Regarding Forward Looking Statements Certain statements in this presentation constitute “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forwarding - looking statements involve known and unknown risks, uncer
Slide 3: Study 400 Objectives
Nasdaq: ACUR Study 400 Objectives 3 Objectives: • Demonstrate LIMITX technology can retard the release of the active ingredient as 3 or more doses are administered in humans • Demonstrate the LTX - 04 formulation achieves blood levels of drug with 1 and/or 2 tablets equivalent to DILAUDID Observatio
Slide 4: Study Cohort Conclusions
Nasdaq: ACUR 4 Study 400 – Cohort 1 Conclusions The Limitx™ Technology can regulate stomach acid and retard the release of active ingredient at 3 or more tablets The current LTX - 04 micro - particle formulation releases drug too slowly for an immediate - release tablet The LTX - 04 micro - particle
Slide 5: Study Cohort Design
Nasdaq: ACUR Study 400 Cohort 1 Design 5 30 subjects enrolled 10 taking 2 tablets 1 0 taking 1 tablets 1 0 taking 3 tablets Single doses of LTX - 04P, LTX - 04S and DILAUDID taken 1 week a apart with blood samples taken and pH monitoring Single doses of LTX - 04P, LTX - 04S and DILAUDID taken 1 week
Slide 6: Study P and S
Nasdaq: ACUR 6 Study 400 LTX - 04P and LTX - 04S • Identical micro - particle formulation in identical amounts in each dose of LTX - 04P and LTX - 04S • LTX - 04S has 45% less the buffering capacity than LTX - 04P • The LTX - 04 test formulations were designed to neutralize different amounts of stom
Slide 7: Study One Tablet Dose Summary
Nasdaq: ACUR 7 Study 400 – One Tablet Dose Summary 0.00 0.20 0.40 0.60 0.80 1.00 1.20 Plasma Conc. Ng/mL DILAUDID LTX-04S LTX-04P ~50% Less 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 Hr * ng/mL Cmax AUC 0 - inf • LTX - 04 @ 50% of Comparator Cmax is indicative of a slow release of drug from t
Slide 8: Cmax of Three S Tablets Proportionally Equal DILAUDID
Nasdaq: ACUR 8 Study 400 – Cmax of Three LTX - 04S Tablets Proportionally Equal DILAUDID 1 2 3 4 5 6 7 0.0 1.0 2.0 3.0 4.0 5.0 6.0 1 Tablet 2 Tablets 3 Tablets Avg. Gastric pH Plasma Conc. ng/mL DILAUDID 1 2 3 4 5 6 7 0.0 1.0 2.0 3.0 4.0 5.0 6.0 1 Tablet 2 Tablets 3 Tablets LTX - 04S Avg. pH at 15 m
Slide 9: Cmax ~22% Lower at 3 Tablets for P than expected
Nasdaq: ACUR 9 Study 400 – Cmax ~22% Lower at 3 Tablets for LTX - 04P than expected 1 2 3 4 5 6 7 0.0 1.0 2.0 3.0 4.0 5.0 6.0 1 Tablet 2 Tablets 3 Tablets Avg. Gastric pH Plasma Conc. ng/mL DILAUDID 1 2 3 4 5 6 7 0.0 1.0 2.0 3.0 4.0 5.0 6.0 1 Tablet 2 Tablets 3 Tablets LTX - 04P Avg. pH at 15 minute
Slide 10: Micro-particle Dissolution versus an earlier prototype (MP-3)
Nasdaq: ACUR 10 LTX - 04 - Micro - particle Dissolution versus an earlier prototype (MP - 3)
Slide 11: Study Cohort Conclusions
Nasdaq: ACUR 11 Study 400 - Cohort 1 Conclusions The Limitx™ Technology can regulate stomach acid and retard the release of active ingredient at 3 or more tablets The current LTX - 04 micro - particle formulation releases drug too slowly for an immediate - release tablet The LTX - 04 micro - particl
Slide 12: Development Next Steps
Nasdaq: ACUR 12 LTX - 04 Development Next Steps • Complete Study AP - LTX - 400 Cohort #2 to confirm results for oral abuse deterrence • Results expected end of June 2016 • Fine tune LTX - 04 micro - particle formulation • Use additional insights from Cohort #1 to assess tablet formulation • Discuss
Slide 13: Acura Pharmaceuticals, Inc.
CONFIDENTIAL Nasdaq: ACUR Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 www.AcuraPharm.com www.Nexafed.com www.Oxaydo.com
Acura Pharmaceuticals — Technical Presentation (April 2016) on 6ix